A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants by Barry C Johnson et al.
Johnson et al. Retrovirology 2012, 9:99
http://www.retrovirology.com/content/9/1/99RESEARCH Open AccessA comparison of the ability of rilpivirine (TMC278)
and selected analogues to inhibit clinically
relevant HIV-1 reverse transcriptase mutants
Barry C Johnson1, Gary T Pauly2, Ganesha Rai3, Disha Patel4, Joseph D Bauman4, Heather L Baker3, Kalyan Das4,
Joel P Schneider2, David J Maloney3, Eddy Arnold4, Craig J Thomas3 and Stephen H Hughes1*Abstract
Background: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor
(NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. In
contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Many
structural analogues of rilpivirine are described in the patent literature, but detailed analyses of their antiviral
activities have not been published. This work addresses the ability of several of these analogues to inhibit the
replication of wild-type (WT) and drug-resistant HIV-1.
Results: We used a combination of structure activity relationships and X-ray crystallography to examine NNRTIs that
are structurally related to rilpivirine to determine their ability to inhibit WT RT and several clinically relevant RT
mutants. Several analogues showed broad activity with only modest losses of potency when challenged with
drug-resistant viruses. Structural analyses (crystallography or modeling) of several analogues whose potencies were
reduced by RT mutations provide insight into why these compounds were less effective.
Conclusions: Subtle variations between compounds can lead to profound differences in their activities and
resistance profiles. Compounds with larger substitutions replacing the pyrimidine and benzonitrile groups of
rilpivirine, which reorient pocket residues, tend to lose more activity against the mutants we tested. These results
provide a deeper understanding of how rilpivirine and related compounds interact with the NNRTI binding pocket
and should facilitate development of novel inhibitors.
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Human immunodeficiency virus type 1 (HIV-1), which
causes acquired immunodeficiency syndrome (AIDS),
poses important problems for world health with an esti-
mated 2.7 million newly infected individuals in 2010 and
an estimated 34 million individuals living with HIV/AIDS
worldwide [1]. However, progress is being made in treat-
ing HIV/AIDS. Highly active antiretroviral therapy
(HAART) is reaching a large number of infected indivi-
duals that, until recently, either had no access to treat-
ment, or relied upon ineffective monotherapies. Modern* Correspondence: hughesst@mail.nih.gov
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reproduction in any medium, provided the orHAART regimens consist of a combination of drugs from
several classes that can include nucleoside reverse tran-
scriptase inhibitors (NRTIs), integrase inhibitors, entry
inhibitors, CCR5 antagonists, protease inhibitors and non-
nucleoside reverse transcriptase inhibitors (NNRTIs) [2].
NNRTIs are used as components of HAART regimens be-
cause of their high specificity and modest toxicity [3].
At present, five NNRTIs have been approved for use in
humans by the U.S. Food and Drug Administration: rilpi-
virine (TMC278) (1), etravirine (2), nevirapine (3), efavir-
enz (4) and delavirdine (5) (Figure 1). Multiple other
chemotypes that have NNRTI activity have been reported,
including numerous structurally unique small molecules.
These compounds bind in the same hydrophobic binding
pocket, and the literature shows a distinct progression inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structures of approved NNRTIs rilpivirine (1),
etravirine (2), nevirapine (3), efavirenz (4) and delaviridine (5).
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dimethylphenyl)acrylonitrile ring system of rilpivirine
(Figure 1, top left ring system of 1) led to improved po-
tency against both WTand mutant RTs.
Although HIV-1 can develop resistance to all of the
approved drugs, the first generation NNRTIs were par-
ticularly susceptible to the rapid emergence of resistant
virus [8]. Rilpivirine and etravirine belong to the chem-
ical class of NNRTIs known as diarylpyrimidines
(DAPYs) that was developed through the collaborative
efforts of pharma and academia [3,9,10]. The DAPY class
of NNRTIs was selected for further study because these
compounds are able to bind and inhibit WT RT and a
number of clinically relevant NNRTI-resistant mutants.
This ability derives from the strategic flexibility of the
compounds within the NNRTI binding pocket [11]. Fur-
ther investigation of the DAPY compounds remains im-
portant because they retain activity against a wide range
of drug-resistant mutants [12].
Clinical trials of rilpivirine, in combination with two
NRTIs, showed that distinct patterns of mutants were
selected in patients experiencing virologic failure (VF)
compared to treatment regimens with efavirenz [13,14].
Patients receiving rilpivirine were more likely to harbor
viruses with NRTI resistance mutations, particularly
M184I, than patients receiving efavirenz. Among the
NNRTI resistance mutations, E138K was selected most
frequently with rilpivirine, while K103N was selected
most frequently with efavirenz. The association between
M184I and E138K selection in patients receiving rilpivir-
ine is noteworthy, because E138K has been shown to re-
store replication capacity to viruses harboring M184
mutations [15]. E138K and M184I were detected in 45%
and 47%, respectively, of patients receiving rilpivirineand experiencing VF [13]. These mutations were found
in 0% and 7%, respectively, of patients experiencing VF
in the efavirenz group. By comparison, clinical trials
revealed that resistance to etravirine is achieved by a
combination of at least three mutations, including V90I,
A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V and
G190A/S [16]. There has been considerable work show-
ing how the DAPY class of NNRTIs bind and inhibit RT
[3,10,17-20]. Several groups have designed derivatives of
these compounds [20,21]. However, much of the SAR
surrounding this class of agents is found primarily in the
patent literature.
The activities of a number of key structural analogues
of both rilpivirine (1) and etravirine (2) against NNRTI-
resistant mutants have not been reported, nor have the
interactions of these analogs with HIV-1 RT been evalu-
ated in structural studies. Such information would pro-
vide a deeper understanding of how these molecules
inhibit WT and drug-resistant RTs and how they can be
engineered to enhance their activity against viruses that
carry resistance mutations. In addition, novel analogues
that select for different patterns of mutations than rilpi-
virine or etravirine could be used as second-line treat-
ment in patients experiencing VF with either of these
drugs, or possibly, in combination with existing drugs.
The difference in mutation profile selected by these
drugs, despite their structural similarities, suggests that
subtle changes can significantly affect the mechanism by
which resistance arises. To pursue the goal of identifying
analogues that will select novel resistance mutations, we
focused our efforts on compounds with specific altera-
tions of the pyrimidine moiety and the 4-amino-
benzonitrile moiety of rilpivirine (1) (Figure 2). We were
motivated to alter only these structural motifs because
the (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile ring
system has been shown to be an important motif for ril-
pivirine binding within the induced NNRTI-binding
pocket [19].
Results and discussion
Inhibitory activity of pyrimidine-based analogues
We examined the effects of rilpivirine and the analogues
on HIV-1 replication using a previously described assay
and report the concentrations at which luciferase re-
porter activity was reduced by half relative to uninhib-
ited controls (EC50) with standard deviations in
parentheses. In the assay, viral vectors that replicate
using WT HIV reverse transcriptase or one of several
mutants (L100I, K103N, V106A, E138K, Y181C, Y188L,
H221Y and the double mutant K103N/Y181C) were
used to infect cells in a single round assay. These
mutants were chosen either because they are known
NNRTI resistance mutations (L100I, K103N, Y181C, and
the K103N/Y181C double mutant), they were selected in
Figure 2 Chemical structures of rilpivirine analogues. Analogues differed from rilpivirine (1, boxed) by the addition of an exocyclic moiety to
the pyrimidine ring in either of its ‘flipped’ conformations (6–9), the replacement of the pyrimidine ring with a 2,6-purine ring system in ‘flipped’
conformations with or without a protecting group (10–13), replacing the 4-benzonitrile moiety in addition to replacing the pyrimidine ring with
a 2,6-purine (14–25), or replacing the pyrimidine ring with a 2,9-purine ring system (26, 27). Differences between each analogue and rilpivirine
are indicated in red.
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or they are positioned to make significant Van der Waals
contacts with rilpivirine (V106A and Y188L). All com-
pounds were initially screened against a panel that
included at least one RT mutant from all three groups
(WT, K103N, E138K, Y181C and Y188L). The cytotox-
icity of the compounds was also determined to establish
the therapeutic index of each of the compounds.
Results from these analyses are shown in Figure 3. Rilpi-
virine (1) demonstrated potent activity versus a vector thatreplicates using WT RT (0.4 ± 0.02 nM) and each of the
single RT mutants (the highest value was 2.3 ± 0.2 nM ver-
sus the Y188L mutant). The CC50 for 1 was 10 ± 0.6 μM.
Pyrimidine analogues that retained the substituted aryl
amines in the same structural location and had either a
nitro or amine substitution added to the 5-position
(Figure 2, analogues 6 and 7) maintained similar activity
profiles as 1 with only slight drops in activity versus the
Y188L mutant (6.8 ± 0.5 nM and 2.3 ± 0.1 nM, respect-
ively). A ‘flipping’ of this structural pattern (Figure 2,
Analogue WT K103N E138K Y181C Y188L CC50 (µM) T.I.
1
(TMC278) 0.4 (0.02) 0.2 (0.03) 0.3 (0.03) 1.3 (0.06) 2.3 (0.2) 10 (0.6) 2.5e4 
6 0.2 (0.01) 0.2 (0.02) 1.4 (0.1) 2.1 (0.1) 6.8 (0.5) 24 (2.1) 1.2e5 
7 0.2 (0.01) 0.3 (0.02) 1.3 (0.1) 1.1 (0.1) 2.3 (0.1) 50 (7.7) 2.5e5 
8 0.9 (0.1) 1.0 (0.1) 4.9 (0.3) 5.3 (0.6) 13 (1.3) 90 (9.1) 1.0e5 
9 0.7 (0.05) 0.7 (0.04) 2.6 (0.3) 4.6 (0.3) 18 (2.0) 19 (0.8) 2.7e4 
10 1.1 (0.2) 1.0 (0.1) 14 (0.6) 9.5 (1.5) >100 (ND) 154 (64) 1.4e5 
11 0.1 (0.01) 0.1 (0.01) 2.9 (0.1) 0.5 (0.1) 13 (0.5) 115 (24) 1.2e6 
12 2.7 (0.4) 1.9 (0.3) 15 (1.2) 6.5 (1.5) 12 (2.3) 83 (11) 3.1e4 
13 0.9 (0.1) 0.4 (0.03) 4.2 (0.3) 1.4 (0.1) 2.0 (0.3) 15 (1.2) 1.7e4 
14 0.3 (0.01) 0.3 (0.03) 1.5 (0.1) 5.9 (0.5) 64 (3.3) 8.0 (0.6) 2.7e4 
15 1.5 (0.1) 0.9 (0.1) 4.7 (0.4) 3.3 (0.4) 17 (1.3) 17 (1.1) 1.1e4 
16 0.2 (0.01) 0.2 (0.02) 1.1 (0.04) 2.3 (0.2) 29 (1.8) 12 (0.6) 6.0e4 
17 1.7 (0.1) 1.3 (0.3) 3.1 (0.5) 2.0 (0.3) 15 (1.6) 12 (0.7) 7.1e3 
18 9.3 (0.7) 4.9 (0.8) 28 (1.5) 56 (5.8) >100 (ND) 13 (0.4) 1.4e3 
19 >100 (ND) >100 (ND) >100 (ND) >100 (ND) >100 (ND) 36 (4.5) < 3.6e2 
20 0.2 (0.01) 0.1 (0.01) 0.8 (0.04) 1.0 (0.06) 19 (1.9) 2.0 (0.3) 1.0e4 
21 0.1 (0.02) 0.6 (0.1) 1.5 (0.1) 1.0 (0.2) 4.4 (1.0) 38 (2.8) 3.8e5 
22 0.6 (0.1) 2.2 (0.3) 8.3 (0.8) 6.1 (1.3) >100 (ND) 57 (4.9) 9.5e4 
23 0.4 (0.1) 1.7 (0.2) 7.9 (0.7) 4.1 (0.9) >100 (ND) 30 (1.4) 7.5e4 
24 0.1 (0.01) 0.6 (0.1) 1.6 (0.2) 3.0 (0.3) 23 (11) 19 (1.3) 1.9e5 
25 19 (4) >100 (ND) >100 (ND) >100 (ND) >100 (ND) 100 (6.5) 5.3e3 
26 4.5 (0.5) 6.5 (0.9) 25 (2.4) 26 (2.9) 91 (25) 21 (0.9) 4.7e3 
27 0.2 (0.01) 0.4 (0.02) 0.7 (0.1) 1.5 (0.1) 9.6 (2.2) 42 (8.6) 2.1e5 
Figure 3 Activities and cytotoxicities of rilpivirine (1) and its analogues. EC50s, as measured by reduction of luciferase reporter activity, are
reported as nM values, CC50s are reported as μM values. Standard deviations are indicated in parentheses. Shading of EC50 values indicates a log
scale: no shading = EC50 <1.0 nM, light gray = EC50 between 1.0 nM and 9.9 nM, dark gray = EC50 between 10 nM and 99nM, black = EC50 ≥100
nM. Therapeutic Index (T.I.) is the ratio of CC50/EC50.
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against the WT RT and K103N mutant and showed more
substantial loss of potency against E138K, Y181C and
Y188L mutants.Inhibitory activity of purine-based analogues
The closest structural homolog to rilpivirine (1) among the
purine derivatives (Figure 2, analogue 11) retained good
potency versus the WT as well as the K103N and Y181C
mutants but showed a modest drop in activity versus the
E138K mutant and a significant drop in activity versus the
Y188L mutant (13 ± 0.5 nM). The ‘flipped’ analogue
(Figure 2, analogue 13) maintained potency similar to 1 for
the WT and each of mutants with the exception of E138K
(4.2 ± 0.3 nM). Retaining the p-methoxybenzyl protecting
group at the 9-position of the purine reduced the potency
of both analogues (Figures 2 and 3, compare 10 to 11 and
12 to 13). Based upon these data, we used 13 as a scaffold
and examined the effects of different substituents in place
of the 4-benzonitrile moiety.The results obtained with these analogues (Figure 2,
analogues 14–25) show that many of the compounds
that are highly active against WT RT show considerable
differences in their ability to inhibit the various mutants.
Attempts to replace the nitrile functionality of the ben-
zonitrile with other moieties resulted in compounds that
were active against the WT and most mutants. However,
these analogues (14–19) showed a significant loss of ac-
tivity versus the Y188L mutant (Figure 3). Replacing the
benzonitrile with alternate ring systems was generally
successful against WT, but Y188L again conferred resist-
ance (analogues 20–25). The benzo[d]thiazole analogue
(21) possessed particularly good activity versus WT and
the mutants, including an EC50 of 4.4 nM against
Y188L. The derivatives incorporating 2,9-purine ring
systems (analogues 26 and 27) were found to possess
very different activities. Placement of the benzonitrile
moiety on the 9-position resulted in an analogue (26)
which showed a significant decrease in activity versus
WT and all of the mutants. However, the incorporation
of the (E)-3-(3,5-dimethylphenyl)acrylonitrile moiety at
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with potencies akin to rilpivirine for WT and all of the
mutants except Y188L, which caused a modest drop in
activity (9.6 ± 2.2 nM).
Selected analogues assayed against additional mutants
Based on the results obtained with the small panel of
mutants, eleven compounds were chosen for testing
against a broader panel which included all the mutants
listed above (K103N, E138K, Y181C and Y188L), and
included rilpivirine (1) as a reference compound. The
analogues 6–9, 11, 13, 20, 21, 26 and 27 were selected
based on their broad potency against the smaller panel
of mutants and/or to determine how their differences
from 1 affected their activities. The K103N/Y181C
double mutant caused a significant loss of potency for 6,
8, 9, 20, 21, 26 and 27 (Figure 4 and Additional file 1:
Table S1), while the analogues 7, 11 and 13 retained
good potency against this mutant. Of particular interest,
the related analogues 7 and 9 differed dramatically in
their ability to inhibit K103N/Y181C RT (EC50 values of
2.2 nM and 47 nM, respectively). These compounds
both possess a central 5-aminopyrimidine moiety that is
‘flipped’ between the two analogues. Keeping the pyrimi-
dine ring in the same conformation as in 1 allows 7 to
retain activity while 9 suffers ~67-fold loss of potency
against the double mutant. A structural explanation for
this difference will be discussed in a later section.
Cytotoxicity
In general, the eleven analogues tested against the
expanded mutant panel showed lower cytotoxicity com-
pared to the other analogues (Figure 3). Only 20 had aFigure 4 Comparison of EC50 values of selected analogs against an ex
are included in Additional file 1: Table S1.lower CC50 than 1 (2.0 μM for 20 versus 10 μM for 1).
CC50 values for analogues 6, 9, 13 and 26 were 1- to
3-fold greater than that of 1. The remaining compounds
(7, 8, 11, 21 and 27) had CC50 values greater than
38 μM (up to 115 μM for 11). The resulting therapeutic
indices (T.I., ratio of CC50 to EC50) ranged from 4.7x10
3
(26) to 1.2x106 (11). By comparison, rilpivirine (1) has a
T.I. of 2.5x104; so, based on the data obtained in cul-
tured cells, many of these analogues compare favourably
to this FDA-approved NNRTI.Crystal structure of 16 bound to WT RT
The crystal structure of the RT/1 complex has been
reported [11]. This structure shows that the (E)-3-(3,5-
dimethylphenyl)acrylonitrile moiety occupied an induced
hydrophobic tunnel formed between residues Y188,
F227, W229 and L234. This moiety is retained in all ana-
logues presented here. To examine the effects of modifi-
cations to other regions of the compound, a crystal
structure of 16 bound to WT RT was solved at 2.3 Å
resolution (Table 1).
Overall, the two compounds bind WT RT very similarly
(Figure 5). The (E)-3-(3,5-dimethylphenyl)acrylonitrile
moiety occupies the hydrophobic tunnel as seen with 1. In
addition, the H-bonds between the central group (pyrimi-
dine in 1, purine in 16) and the backbone amide and
carbonyl groups of K101 are maintained. The ring of the
4-anisole group of 16 overlays with the ring of the
4-benzonitrile group of 1. The most pronounced differ-
ence is between the bent nature of the methoxy function-
ality of 4-anisole (16) and the linear nature of the cyano
functionality of 4-benzonitrile (1). This difference appearspanded set of mutants. Values for mutants not shown in Figure 3
Table 1 X-ray data and refinement statistics
HIV-1 WT RT/16 K103N/Y181C mutant HIV-1 RT/21
Protein Data Bank (PDB) accession code 4I2P 4I2Q
Space group C2 C2
Cell constants (a, b, c in Å; β in º) 162.65, 72.99, 109.50; 100.59 162.60, 72.95, 108.54; 100.70
Resolution range (Å) 50.00 – 2.30 50.00 – 2.70
Completeness (%) 98.8 99.2
Rmerge 0.085 0.084
Average I/σI 15.0 16.5
Sigma cut-off (I) |I| < −3.0σ |I| < −3.0σ
Refinement Statistics
Total no. of atoms (solvent atoms) 8,258 (309) 8,094 (146)
Resolution (Å) 2.30 2.70
No. of reflections 55,924 34,219
Rwork 0.212 0.215
Rfree 0.260 0.286
Ramachandran statistics (% of residues in favored/disallowed regions) 99.48/0.52 99.90/0.10
RMSD bond length (Å) 0.009 0.009
RMSD bond angles (º) 1.120 1.258
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compounds against WT RT (Figure 3).
Starting with the crystal structures of these two com-
pounds bound to WT RT, models were generated of the
complexes with Y188L RT. In both models, the com-
pounds are shifted approximately one angstrom relative
to their positions in the respective WT RT crystal struc-
tures. The linear nature of the cyano functionality of the
4-benzonitrile moiety in 1 allows it to extend past the
side chain of F227 with only about 30º rotation around
the Cβ-Cγ bond. The 4-anisole’s methoxy group (16)
would cause a greater steric clash with the F227 side
chain as it is positioned in the WT RT than would the
4-benzonitrile (1). As a result, a shift of the backbone of
the β12-β13 hairpin is observed in the Y188L/16 model
relative to its position in the WT/16 crystal structure
(Figure 5). The F227 Cα is displaced by 1.2 Å and both
the Cβ and Cγ atoms are displaced by 1.3 Å. This dis-
placement is propagated throughout the loop including
W229; the Cα atom of this residue is displaced by 2.1 Å.
The repositioning of this hairpin provides a possible ex-
planation for the observed loss of potency for 16 against
Y188L RT.
Crystal structure of 21 bound to K103N/Y181C RT
A structural study comparing rilpivirine binding to WT
and mutant RTs revealed that the drug is able to retain
its inhibitory activity by adapting its binding mode (wig-
gling and jiggling) to accommodate changes in the land-
scape of the binding pocket caused by NNRTI resistance
mutations [11]. This hypothesis was tested by analyzingthe structures of several mutant RTs with rilpivirine (1)
bound and by comparing these binding modes to the
binding modes of other NNRTIs, such as tert-
butyldimethylsilyl-spiroaminooxathioledioxide (TSAO)
[22]. To better understand why one of the rilpivirine
analogues was not highly effective at inhibiting mutant
RTs, we determined the crystal structure of the K103N/
Y181C double-mutant RT in complex with 21 at 2.7 Å
resolution (Table 1).
The double mutant K103N/Y181C RT confers ~8-fold
resistance to riplivirine (1) and >1000-fold resistance to
21. The overall binding mode of 21 (Figure 6) to the
mutant RT is similar to and superimposes well with that
of rilpivirine (1) [11]. The (E)-3-(3,5-dimethylphenyl)
acrylonitrile moiety of 21, common to both agents, oc-
cupies the hydrophobic core of the pocket and interacts
with the aromatic side chains of Y188 and W229.
Analogue 21 has a bulkier benzothiazole moiety substi-
tuted for the benzonitrile group of rilpivirine (1). As a
result, the benzothiazole of 21 extends nearly 2 Å to-
wards F227 and moved away from P236 compared to
the nitrile group of 1. The benzothiazole group of 21
has extended interactions with the side chains of V106,
F227, and Y318. The side chain of F227 is reoriented to
accommodate the benzothiazole group of 21, has moved
towards P225, and undergoes a ~40º rotation about the
Cβ-Cγ bond relative to the RT-rilpivirine structure. Con-
sequently, the flexible 222–226 loop is repositioned;
however, the cis-peptide link between P225-P226
observed in the rilpivirine co-crystal is also present in
the 21 co-crystal. The benzothiazole moiety of 21 does
Figure 5 Overlay of crystal structures and models of 1 and 16
bound to RT. Co-crystal structures of WT RT bound to 1 (gray) and
16 (green) show only minimal differences in the position of the
compound and the conformation of the binding pocket. This is
consistent with the similar activity of the two compounds against
WT RT (0.2nM for 1 and 0.4nM for 16). Models were generated for
each compound bound to Y188L RT (1: magenta, 16:cyan). Both
models show the compound positioned approximately one
angstrom further into the binding pocket than in the respective WT
co-crystal structure. This results in a repositioning of the F227 and
W229 side chains and a shift in the overall positioning of the β12-β13
hairpin (shown as a ribbon). These differences in the modeled
interactions are consistent with the observed difference in antiviral
activities against vectors using Y188L RT (2.3nM for 1 and 29nM for 16).
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β13-β14 sheet, unlike that seen when TSAO or delavir-
dine binds to RT [22,23].
In 21, the central pyrimidine ring of rilpivirine (1) is
substituted by a purine that extends toward the side
chains of K101 (p66) and E138 (p51) at the putative en-
trance to the inhibitor binding pocket. Both of these
side-chains are involved with the entry/exit of NNRTIs
into/out of the pocket, and a hydrogen bond exists be-
tween the two in most RT/NNRTI structures. In the
double mutant K101E/E138K, the H-bond is retained,
but these mutations cause a significant loss of potency
to several preclinical TSAO-derived NNRTIs [22]. This
suggests that the presence of specific amino acids at
positions 101 and 138 may affect the binding of other
NNRTIs. The positioning of the purine moiety of 21
causes significant rearrangements of the K101 and E138side chains, which breaks the H-bond between these two
residues and forms extensive hydrophobic contacts with
methylene groups of both side chains. Interestingly, the
N7 atom of the purine ring forms an H-bond with the
backbone amide of K101 analogous to that seen with the
pyrimidine ring of rilpivirine. The purine moiety also
has extensive interactions with L100, the mutated
K103N and V106. The mutated K103N side chain has
more hydrophobic stacking interactions with the purine
moiety of 21 than with the pyrimidine of rilpivirine (1).
Our structure indicates that the benzothiazole moiety
maintains inhibitor-protein interactions without requir-
ing significant rearrangement of the pocket, apart from
reorienting the side chains of K101, E138 (p51), and
F227 (Figure 6). Also, the disruption of the K101-E138
H-bond may affect the dissociation of 21 in a manner
that is not observable in the co-crystal. The positional
constraints on the amino acid residues that are parts of
the hydrophobic tunnel and the entrance to the pocket
may explain why 21 is less susceptible to pocket
mutations.Modeling other RTs and compounds
Several of the analogues showed significantly different ac-
tivities against a particular RT mutant despite having only
relatively modest structural changes relative to the parent
compound. For example, compounds 7 and 9 differ only
in the orientation of the central 5-aminopyrimidine moiety.
This subtle change results in an EC50 for 9 that is ~21-fold
greater than that of 7 against the K103N/Y181C mutant.
Models of both of these complexes were generated from
the crystal structure of 1 bound to this mutant [11].
The models show no significant changes to either the
β12-β13-β14 sheet or the K101-E138 salt bridge. How-
ever, the solvent-exposed surface of the pyrimidine is
shifted nearly an angstrom when the two models are
compared to each other. This positions the exocyclic
amine of 9 such that it cannot form the H-bond to the
K101 backbone amide seen with 1 (Figure 7). In con-
trast, this H-bonding is maintained with 7. These models
also differ in the orientation of a water molecule forming
a bridge to the backbone carbonyl of E138. The exocyc-
lic amine and aryl amine of 7 serve as donors to bind
the same oxygen atom of a water molecule. These inter-
actions position the water differently than it appears in
the model with 9, where the pyrimidine’s N3 serves as
an acceptor and the aryl amine as a donor to bind the
same water molecule. The orientation of that water mol-
ecule could result in a weaker interaction with the E138
backbone. This subtle change in the compound, and the
corresponding loss of activity against the K103N/Y181C
mutant, highlights two potential interactions that need
to be considered in the design of additional derivatives.
Figure 6 NNRTI-binding pocket superposition of the crystal structures of K103N-Y181C mutant RT/21 (yellow protein and green
ligand) and K103N/Y181C mutant RT/rilpivirine (PDB ID. 3BGR; blue protein and gray ligand). The hydrogen bonds are represented as
dotted lines, and the most significant structural differences are indicated by red arrows.
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Analogues 6 and 8 have 5-nitropyrimidine central moi-
eties in the ‘flipped’ orientations. These nitro groups ap-
pear capable of forming intramolecular H-bonds with
the aryl amines bound to the 6-position of the pyrimi-
dine ring. These interactions may restrict the flexibility
of these analogues. This observation is consistent with
the similar profiles of 8 and 26 and those of 6 and 27.
The potential intramolecular H-bonds may mimic the
covalent restriction imposed by the purine ring systems
of 26 and 27.Conclusions
In summary, we have designed and synthesized several
small molecules that are structurally related to the re-
cently approved NNRTI rilpivirine (1) and tested them
for their ability to inhibit the replication of viral vectors
that carry WT RT or several clinically relevant mutant
RTs. This data set provides insights into structure-
activity relationships of this family of compounds. One
agent, a purine analogue with a benzo[d]thiazole ap-
pendage at the 6-position (analogue 21), possessed good
activity versus all single mutants tested, but showed little
activity against the K103N/Y181C double mutant. To
understand the molecular basis of this loss of potency,
we determined the crystal structure of the double-
mutant K103N/Y181C RT in complex with 21. This
structure provided insights into how this analogue failed
to maintain potency versus specific RT mutants. Mo-
lecular modeling also proved useful in assessing how
other analogues interact with RT.
Three analogues were identified (7, 11 and 13) that
show nearly as broad potency and cytotoxicity compar-
able to, or more favourable than, that of rilpivirine (1).
These three compounds showed some loss of potency(four- to fourteen-fold) against E138K and 11 lost some
potency against Y188L (nearly six-fold). It is noted that
rilpivirine is comparably active against vectors harbour-
ing either WT or E138K RT in this assay despite the fre-
quent selection of this mutant in clinical trials [13,24].
These trials used treatment regimens that included two
NRTIs (TDF/FTC in the ECHO trial and TDF/FTC,
zidovudine/lamivudine or abacavir/lamivudine in the
THRIVE trial). E138K has been shown to compensate
for the loss of viral fitness associated with certain NRTI
resistance mutations, particularly M184I or M184V [15].
It is possible that the frequent selection of E138K is
driven more by a need to restore fitness to NRTI-
resistant RTs than by a significant affect on rilpivirine re-
sistance, consistent with a higher rate of NRTI-resistant
mutants selected in the rilpivirine group than in the efa-
virenz group in the clinical trials [13]. Controlling HIV
infection must be done with combinations of drugs that
work cooperatively against known resistant mutants. If
any of these three analogues select for a different set of
mutants than does rilpivirine, they may be useful in
patients experiencing virologic failure on a rilpivirine
regimen. Such selection experiments, and the synthesis
and testing of additional analogues, represent future
steps in this continuing effort.Methods
Synthesis
All compounds shown in Figure 2 were synthesized and
assayed for HIV inhibitory activity and cytotoxicity. Syn-
thetic protocols and representative 1H NMR chemical
shift data are included as Additional file 1. Briefly, aryl
amines were coupled to a PMB-protected 2,6 dichloro-
9H-purine starting reagent at the 6-position, followed by
addition at the 2-position using a modified Buchwald-
Figure 7 Models of analogues 7 (cyan) and 9 (magenta) bound
to K103N/Y181C RT. (A) Overlay of the two compounds as
modeled in the binding pocket of K103N/Y181C HIV-1 RT. (B) The
exocyclic amine in 9 cannot H-bond with the backbone NH of K101,
as seen in crystal structures of 1. The N3 and linker NH both bind a
water molecule that forms a bridge to the backbone carbonyl of
E138. (C) The H-bonds with the backbone of K101 are restored in 7.
In addition, the exocyclic amine and linker NH both H-bond a water
molecule in a different orientation than is seen with 9.
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Analogues 26 and 27 were synthesized by modifying a
synthetic protocol described in the patent literature [27].
Virion production
Procedures for virion production and cell-based assay
have been reported [28]. Briefly, all cell cultures were
maintained in Dulbecco’s modified Eagle’s medium (Invi-
trogen, Carlsbad, CA) with 5% (v/v) fetal bovine serum,
5% newborn calf serum, penicillin (50 units/mL) and
streptomycin (50 μg/mL) (Quality Biological, Gaithers-
burg, MD). VSV-g pseudotyped virions were produced
by plating 9x105 293 T cells in a 100 mm plate, then
transfecting with the pNLNgoMIVR+ΔEnv.LUC (10 μg)
and pHCMV-g (3 μg) plasmids by calcium phosphate
precipitation on the following day. Transfected cells
were incubated at 37°C for 8 hrs, washed twice with
PBS, fresh media was added and the cells were returned
to the incubator for 48 hrs. The pNLNgoMIVR+ΔEnv.
LUC plasmid encodes the HIV-1 genome with an Env
deletion and either WT HIV-1 RT, or one of the follow-
ing mutants: L100I, K103N, V106A, E138K, Y181C,
Y188L, H221Y, or K103N/Y181C. Supernatants from
each plate were clarified by low-speed centrifugation
(3,000xg for 20 min), then treated with 200 U DNase I
(Roche Applied Science, Mannheim, Germany) at room
temperature for 3 hours. Viral supernatants were stored
at −20°C until used.
Infectivity assays
One day prior to infection, 100 μL of human osteosar-
coma (HOS) cells were added to each well of a 96-well
plate at a density of 4x104 cells/mL. Plates were incu-
bated overnight at 37°C. On the day of infection, 10X
drug stocks were prepared by serial dilution in media
from an initial 10 mM stock solution in DMSO. Cells in
the 96-well plate were pre-treated by the addition of 22
μL of the appropriate drug stock and returned to the in-
cubator for 3 hours. Thawed virus stocks were diluted
1:2 in media, then 100 μL of virus was added to the pre-
treated cells, bringing the final drug concentrations to
0.1 nM to 100 nM, with DMSO-treated cells (no drug)
serving as a reference. In addition, 12 wells of cells trea-
ted with media and no virus served as negative controls.
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42 hours, at which time the luciferase activity was deter-
mined using Steady-Lite Plus kits (PerkinElmer, Wal-
tham, MA). Background luciferase activity, as measured
for the negative controls, was subtracted from the activ-
ities measured for each infected well. Drug-free, DMSO-
treated wells were normalized to 100% infectivity. Infect-
ivity at each drug concentration was determined as a
percentage of these drug-free infections. Drug concen-
tration versus percent infectivity was plotted for each
RT-inhibitor combination, and the data were fit to a
four-parameter sigmoidal curve using KaleidaGraph 4.0
(Synergy Software, Reading, PA). The inflection point of
each curve is reported as the IC50. All values are the
mean of triplicate infections.
Cytotoxicity assays
One day prior to treatment, HOS cells were prepared in
96-well plates as described for the infectivity assays, ex-
cept that 12 wells per plate were treated with cell-free
media to serve as negative controls. The following day,
serial dilutions of drug stocks were prepared in media
from 10 mM stocks in DMSO. Each well received 11 μL
of the appropriate drug concentration or DMSO-treated,
drug-free media. Final drug concentrations ranged from
0.5 μM to 300 μM. The drug-free wells served as refer-
ences. Plates were then incubated at 37°C for 48 hours.
Cell viability was determined using luciferase reporter
ATP-Lite kits (PerkinElmer). As described for the infect-
ivity assays, drug-free reference wells were normalized to
100%, and viabilities at different drug concentrations
were determined as a percentage of these references.
Data were plotted and analyzed in the same manner as
the IC50 data, with the inflection points of the curves
reported as CC50.
Crystallography
RT was expressed and purified as described previously
[29]. RT (WT and mutant) was co-crystallized with 16
and 21 at 4°C by vapor diffusion in micro-seeded hang-
ing drops containing 1.2 μL each of 20 mg/mL protein
(in a solution of 10 mM Tris pH 8.0, 75 mM NaCl,
0.30% (w/v) β-octyl glucopyranoside, 2% (v/v) DMSO,
and 0.5 mM 16 or 21 pre-incubated for 10 min at 25°C)
and a reservoir solution containing 50 mM imidazole
pH 6.6, 100 mM ammonium sulfate, 15 mM manganese
sulfate, 10 mM spermine, 5 mM TCEP, 11% (w/w) PEG
8000, and 5% PEG 400. The chosen crystals were soaked
for ~20 s in a solution containing 50 mM imidazole pH
6.6, 50 mM ammonium sulfate, 15 mM manganese sul-
fate, 10 mM spermine, 12% (w/w) PEG 8000, 6% (w/w)
PEG 400, and 26% (v/v) ethylene glycol. The crystal was
subsequently flash-cooled and stored in liquid N2. Data
collection was performed at the Cornell High EnergySynchrotron Source (CHESS) F1 beamline. The diffrac-
tion data were indexed, processed, scaled and merged
using HKL2000I [30]. The structure was refined using
Phenix [31] and model building was done using COOT
[32]. The crystallographic data and refinement statistics
are listed in Table 1.
Computer modeling
All computer modeling was done using MOE 2009.10 or
MOE2011.10 (Chemical Computing Group, Montreal,
Quebec, Canada). The model of 1 bound to Y188L RT
was based on the previously reported crystal structure of
the WT RT/1 complex (PDB ID: 2ZD1 [11]). Models of
complexes with 16 and 21 were based on the crystal
structures presented in the current work (PDB IDs 4I2P
and 4I2Q, respectively). Models of 7 and 9 bound to
K103N/Y181C RT were based on the K103N/Y181C
RT/1 crystal structure (PDB ID: 3BGR [11]).
Additional file
Additional file 1: Synthetic schemes used to synthesize purine
analogues of rilpivirine. Scheme 1 was used to synthesize analogues
10-25 while Scheme 2 was used to synthesize analogues 26 and 27.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BJ performed the infectivity and cytotoxicity assays and carried out the
molecular modeling. GP, GR, HB, JS, DM and CT contributed to the synthesis
of compounds. DP, JB, KD and EA performed the crystallographic studies. EA,
CT and SH designed the experiments. BJ, KD, DM, EA, CT and SH drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by the Intramural Research Programs of the
National Cancer Institute, the National Human Genome Research Institute,
the National Center for Advancing Translational Sciences, the Intramural AIDS
Targeted Antiviral Program (IATAP), and an R37 Merit Award AI 27690 to E.A.
We acknowledge the Cornell High Energy Synchrotron Source (CHESS) for
X-ray diffraction data collection.
Author details
1HIV Drug Resistance Program, National Cancer Institute, Frederick National
Laboratory for Cancer Research, P.O. Box BBuilding 539, Room 130A,
Frederick, MD 21702-1201, USA. 2Chemical Biology Laboratory, Frederick
National Laboratory for Cancer Research, Frederick, MD, USA. 3NIH Chemical
Genomics Center, National Center for Advancing Translational Sciences, NIH,
9800 Medical Center Drive, Bethesda, MD MSC 3370, USA. 4Center for
Advanced Biotechnology and Medicine and Department of Chemistry and
Chemical Biology, Rutgers University, Piscataway, NJ, USA.
Received: 6 September 2012 Accepted: 12 November 2012
Published: 5 December 2012
References
1. HIV/AIDS.: http://www.who.int/topics/hiv_aids/en/.
2. Hartman TL, Buckheit RW Jr: The continuing evolution of HIV-1 therapy:
identification and development of novel antiretroviral agents targeting
viral and cellular targets. Mol Biol Int 2012, 2012:401965.
3. Li D, Zhan P, De Clercq E, Liu X: Strategies for the design of HIV-1 non-
nucleoside reverse transcriptase inhibitors: lessons from the
Johnson et al. Retrovirology 2012, 9:99 Page 11 of 11
http://www.retrovirology.com/content/9/1/99development of seven representative paradigms. J Med Chem 2012,
55:3595–3613.
4. Jorgensen WL, Bollini M, Thakur VV, Domaoal RA, Spasov KA, Anderson KS:
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys
variant of HIV reverse transcriptase. J Am Chem Soc 2011,
133:15686–15696.
5. Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R,
Freeman A, Ferris RG, Andrews CW, et al: Structural basis for the improved
drug resistance profile of new generation benzophenone non-
nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 2008,
51:5000–5008.
6. Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, Rudd D, Munshi
V, Bahnck C, Felock PJ, et al: Biaryl ethers as novel non-nucleoside reverse
transcriptase inhibitors with improved potency against key mutant
viruses. J Med Chem 2009, 52:7163–7169.
7. Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP,
Billedeau JR, Gleason SK, Hirschfeld D, et al: Design of annulated pyrazoles
as inhibitors of HIV-1 reverse transcriptase. J Med Chem 2008,
51:7449–7458.
8. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD: Nonnucleoside
reverse transcriptase inhibitor resistance and the role of the second-
generation agents. Ann Pharmacother 2010, 44:157–165.
9. De Corte BL: From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)
benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of
research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
J Med Chem 2005, 48:1689–1696.
10. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers
HM, Daeyaert F, Ludovici DW, Kukla MJ, et al: Roles of conformational and
positional adaptability in structure-based design of TMC125-R165335
(etravirine) and related non-nucleoside reverse transcriptase inhibitors
that are highly potent and effective against wild-type and drug-resistant
HIV-1 variants. J Med Chem 2004, 47:2550–2560.
11. Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH,
Arnold E: High-resolution structures of HIV-1 reverse transcriptase/
TMC278 complexes: strategic flexibility explains potency against
resistance mutations. Proc Natl Acad Sci USA 2008, 105:1466–1471.
12. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans
D, Van Craenenbroeck E, Picchio G, Rimsky LT: TMC278, a next-generation
nonnucleoside reverse transcriptase inhibitor (NNRTI), active against
wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010,
54:718–727.
13. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven
K, Picchio G: Genotypic and phenotypic characterization of HIV-1 isolates
obtained from patients on rilpivirine therapy experiencing virologic
failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
J Acquir Immune Defic Syndr 2012, 59:39–46.
14. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA,
Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, et al: Rilpivirine
versus efavirenz with two background nucleoside or nucleotide reverse
transcriptase inhibitors in treatment-naive adults infected with HIV-1
(THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011,
378:229–237.
15. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg
MA: Compensation by the E138K mutation in HIV-1 reverse transcriptase
for deficits in viral replication capacity and enzyme processivity
associated with the M184I/V mutations. J Virol 2011, 85:11300–11308.
16. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W,
Trottier B, Peeters M, Vingerhoets J, et al: Efficacy and safety of TMC125
(etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:
24-week results from a randomised, double-blind, placebo-controlled
trial. Lancet 2007, 370:39–48.
17. Chen X, Zhan P, Li D, De Clercq E, Liu X: Recent advances in DAPYs and
related analogues as HIV-1 NNRTIs. Curr Med Chem 2011, 18:359–376.
18. Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ,
Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, et al: Synthesis of novel
diarylpyrimidine analogues and their antiviral activity against human
immunodeficiency virus type 1. J Med Chem 2005, 48:2072–2079.
19. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L,
Vinkers M, Guillemont J, Pasquier E, et al: In search of a novel anti-HIV
drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]
benzonitrile (R278474, rilpivirine). J Med Chem 2005, 48:1901–1909.
20. Liang YH, Feng XQ, Zeng ZS, Chen FE, Balzarini J, Pannecouque C, De
Clercq E: Design, synthesis, and SAR of naphthyl-substituted
Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse
transcriptase. ChemMedChem 2009, 4:1537–1545.
21. Sun LQ, Zhu L, Qian K, Qin B, Huang L, Chen CH, Lee KH, Xie L: Design,
synthesis, and preclinical evaluations of novel 4-substituted 1,5-
diarylanilines as potent HIV-1 Non-nucleoside reverse transcriptase
inhibitor (NNRTI) drug candidates. J Med Chem 2012, 55:7219–7229.
22. Das K, Bauman JD, Rim AS, Dharia C, Clark AD Jr, Camarasa MJ, Balzarini J,
Arnold E: Crystal structure of tert-butyldimethylsilyl-
spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1
reverse transcriptase (RT) redefines the elastic limits of the non-
nucleoside inhibitor-binding pocket. J Med Chem 2011, 54:2727–2737.
23. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK, Stuart DI:
Unique features in the structure of the complex between HIV-1 reverse
transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain
resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci
USA 1997, 94:3984–3989.
24. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H,
Johnson MA, Saag M, Supparatpinyo K, et al: Efficacy and safety of
rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-
1-infected patients: pooled results from the phase 3 double-blind
randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012,
60:33–42.
25. Kelley JL, Linn JA, Krochmal MP, Selway JW: 9-Benzyl-6-(dimethylamino)-
9H-purines with antirhinovirus activity. J Med Chem 1988, 31:2001–2004.
26. Wolfe JP, Buchwald SL: Scope and limitations of the Pd/BINAP-catalyzed
amination of aryl bromides. J Org Chem 2000, 65:1144–1157.
27. Guillemont JEG, Paugam M, Delest BFM, Heeres J, Lewi PJ, Janssen PAJ, Arts
FJJH: HIV inhibiting bicyclic pyrimidine derivatives. USA: Office USPaT ed; 2008.
28. Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH: 40-C-methyl-20-
deoxyadenosine and 40-C-ethyl-20-deoxyadenosine inhibit HIV-1
replication. Antimicrob Agents Chemother 2011, 55:2379–2389.
29. Bauman JD, Das K, Ho WC, Baweja M, Himmel DM, Clark AD Jr, Oren DA,
Boyer PL, Hughes SH, Shatkin AJ, Arnold E: Crystal engineering of HIV-1
reverse transcriptase for structure-based drug design. Nucleic Acids Res
2008, 36:5083–5092.
30. Otwinowski Z, Minor W: Crystallography of biological macromolecules.
Boston: Kluwer Academic Publishers; 2001.
31. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ,
Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al: PHENIX: a comprehensive
Python-based system for macromolecular structure solution. Acta
Crystallogr D Biol Crystallogr 2010, 66:213–221.
32. Emsley P, Cowtan K: Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 2004, 60:2126–2132.
doi:10.1186/1742-4690-9-99
Cite this article as: Johnson et al.: A comparison of the ability of
rilpivirine (TMC278) and selected analogues to inhibit clinically relevant
HIV-1 reverse transcriptase mutants. Retrovirology 2012 9:99.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
